Dynatronics Corporation (DYNT) versus Accelerate Diagnostics (AXDX) Head to Head Comparison

Dynatronics Corporation (NASDAQ: DYNT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Dynatronics Corporation and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dynatronics Corporation -7.24% -152.17% -14.67%
Accelerate Diagnostics -5,062.48% -67.44% -63.75%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Dynatronics Corporation and Accelerate Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynatronics Corporation 0 0 0 0 N/A
Accelerate Diagnostics 0 0 2 0 3.00

Accelerate Diagnostics has a consensus target price of $33.00, indicating a potential upside of 52.07%. Given Accelerate Diagnostics’ higher possible upside, analysts clearly believe Accelerate Diagnostics is more favorable than Dynatronics Corporation.

Institutional and Insider Ownership

14.6% of Dynatronics Corporation shares are held by institutional investors. Comparatively, 38.7% of Accelerate Diagnostics shares are held by institutional investors. 63.9% of Dynatronics Corporation shares are held by company insiders. Comparatively, 51.4% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Dynatronics Corporation and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Dynatronics Corporation $32.72 million 0.29 -$261,530.00 ($1.05) -2.48
Accelerate Diagnostics $1.29 million 930.21 -$61.92 million ($1.23) -17.64

Dynatronics Corporation has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Dynatronics Corporation, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Dynatronics Corporation has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.

About Dynatronics Corporation

Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Dynatronics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatronics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply